

# Patrizia Nanni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/152536/publications.pdf>

Version: 2024-02-01

100  
papers

4,850  
citations

87723

38  
h-index

98622

67  
g-index

101  
all docs

101  
docs citations

101  
times ranked

5797  
citing authors

#	ARTICLE	IF	CITATIONS
1	IFN- $\gamma$ and CD38 in Hyperprogressive Cancer Development. <i>Cancers</i> , 2021, 13, 309.	1.7	17
2	Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft. <i>Scientific Reports</i> , 2021, 11, 1563.	1.6	6
3	HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy. <i>Cells</i> , 2021, 10, 1808.	1.8	2
4	Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. <i>Oncogenesis</i> , 2021, 10, 77.	2.1	14
5	Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 1768-1779.	2.0	31
6	Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. <i>Scientific Reports</i> , 2019, 9, 12174.	1.6	52
7	Cancer Vaccines Co-Targeting HER2/Neu and IGF1R. <i>Cancers</i> , 2019, 11, 517.	1.7	7
8	Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis. <i>BMC Cancer</i> , 2019, 19, 126.	1.1	7
9	Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model. <i>Cancers</i> , 2019, 11, 1889.	1.7	15
10	OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis. <i>Oncolmmunology</i> , 2018, 7, e1465164.	2.1	3
11	Virus-like particle display of HER2 induces potent anti-cancer responses. <i>Oncolmmunology</i> , 2018, 7, e1408749.	2.1	82
12	A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1881-1892.	1.9	33
13	Cancer immunoprevention: from mice to early clinical trials. <i>BMC Immunology</i> , 2018, 19, 16.	0.9	9
14	A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors. <i>PLoS Pathogens</i> , 2018, 14, e1007209.	2.1	51
15	Immunoprevention. , 2017, , 2223-2228.		1
16	HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. <i>Oncotarget</i> , 2017, 8, 54444-54458.	0.8	19
17	The Promise of Preventive Cancer Vaccines. <i>Vaccines</i> , 2015, 3, 467-489.	2.1	38
18	Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. <i>Breast Cancer Research</i> , 2015, 17, 70.	2.2	11

#	ARTICLE	IF	CITATIONS
19	Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases. <i>Oncotarget</i> , 2015, 6, 34774-34787.	0.8	62
20	Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment. <i>Human Molecular Genetics</i> , 2014, 23, 1453-1466.	1.4	96
21	Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. <i>Cancer Research</i> , 2014, 74, 6248-6259.	0.4	63
22	Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. <i>Breast Cancer Research</i> , 2014, 16, R10.	2.2	27
23	Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. <i>BMC Genomics</i> , 2014, 15, S1.	1.2	20
24	Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. <i>Journal of Translational Medicine</i> , 2014, 12, 122.	1.8	15
25	Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. <i>Oncotarget</i> , 2014, 5, 108-119.	0.8	12
26	Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas. <i>Oncotarget</i> , 2014, 5, 11924-11938.	0.8	10
27	Immunoprevention. , 2014, , 1-6.		0
28	Preclinical vaccines against mammary carcinoma. <i>Expert Review of Vaccines</i> , 2013, 12, 1449-1463.	2.0	11
29	Preclinical HER-2 Vaccines: From Rodent to Human HER-2. <i>Frontiers in Oncology</i> , 2013, 3, 151.	1.3	7
30	Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus. <i>PLoS Pathogens</i> , 2013, 9, e1003155.	2.1	36
31	The Molecular Basis of Herpesviruses as Oncolytic Agents. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1795-1803.	0.9	4
32	Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2 <sup>-/-</sup> ;Il2rg <sup>-/-</sup> Mice and Treatment with PI3K Inhibitor. <i>PLoS ONE</i> , 2012, 7, e39626.	1.1	78
33	HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines. <i>Vaccine</i> , 2011, 29, 4690-4697.	1.7	4
34	Vaccines and Other Immunological Approaches for Cancer Immunoprevention. <i>Current Drug Targets</i> , 2011, 12, 1957-1973.	1.0	39
35	2011: the immune hallmarks of cancer. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 319-326.	2.0	316
36	Rethinking herpes simplex virus: the way to oncolytic agents. <i>Reviews in Medical Virology</i> , 2011, 21, 213-226.	3.9	63

#	ARTICLE	IF	CITATIONS
37	A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene <i>MTND1</i> , an <i>Oncojanus</i> Function. <i>Cancer Research</i> , 2011, 71, 6220-6229.	0.4	90
38	Immunoprevention. , 2011, , 1827-1830.		0
39	Modeling the competition between lung metastases and the immune system using agents. <i>BMC Bioinformatics</i> , 2010, 11, S13.	1.2	44
40	Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER2/neu oncogene-driven animal model system. <i>Proteomics</i> , 2010, 10, 3835-3853.	1.3	10
41	Immunoprevention and Immunotherapy of Mammary Carcinoma. <i>Breast Journal</i> , 2010, 16, S39-S41.	0.4	3
42	<i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations. <i>Cancer Research</i> , 2010, 70, 7755-7763.	0.4	78
43	High metastatic efficiency of human sarcoma cells in Rag2 <sup>fl/c</sup> double knockout mice provides a powerful test system for antimetastatic targeted therapy. <i>European Journal of Cancer</i> , 2010, 46, 659-668.	1.3	26
44	Molecular and cellular biology of rhabdomyosarcoma. <i>Future Oncology</i> , 2009, 5, 1449-1475.	1.1	91
45	Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9039-9044.	3.3	83
46	Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 754-761.	1.9	20
47	Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. <i>Vaccine</i> , 2009, 27, 2065-2069.	1.7	1
48	Antimetastatic Activity of a Preventive Cancer Vaccine. <i>Cancer Research</i> , 2007, 67, 11037-11044.	0.4	47
49	Preclinical <i>In vivo</i> Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma. <i>Clinical Cancer Research</i> , 2007, 13, 1322-1330.	3.2	126
50	Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. <i>International Journal of Cancer</i> , 2007, 121, 88-94.	2.3	5
51	Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. <i>Pathology and Oncology Research</i> , 2007, 13, 336-339.	0.9	8
52	Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing's sarcoma. <i>European Journal of Cancer</i> , 2006, 42, 91-96.	1.3	69
53	Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. <i>European Journal of Cancer</i> , 2006, 42, 680-687.	1.3	2
54	Vaccines for tumour prevention. <i>Nature Reviews Cancer</i> , 2006, 6, 204-216.	12.8	312

#	ARTICLE	IF	CITATIONS
55	Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. <i>International Journal of Cancer</i> , 2006, 119, 1039-1046.	2.3	49
56	CD99 Acts as an Oncosuppressor in Osteosarcoma. <i>Molecular Biology of the Cell</i> , 2006, 17, 1910-1921.	0.9	60
57	CD25+ Regulatory T Cell Depletion Augments Immunotherapy of Micrometastases by an IL-21-Secreting Cellular Vaccine. <i>Journal of Immunology</i> , 2006, 176, 1750-1758.	0.4	96
58	Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 599-610.	2.0	14
59	Cancer immunoprevention. <i>Future Oncology</i> , 2005, 1, 57-66.	1.1	43
60	Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary Carcinoma. <i>American Journal of Pathology</i> , 2005, 166, 1205-1216.	1.9	43
61	Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases the Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells. <i>Cancer Research</i> , 2004, 64, 1730-1736.	0.4	83
62	Immunological Prevention of a Multigene Cancer Syndrome. <i>Cancer Research</i> , 2004, 64, 8428-8434.	0.4	19
63	Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine. <i>Cancer Research</i> , 2004, 64, 4001-4009.	0.4	87
64	Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN- $\gamma$ and B Cell Dependent. <i>Journal of Immunology</i> , 2004, 173, 2288-2296.	0.4	88
65	Apc10.1: AnApcMin/+ intestinal cell line with retention of heterozygosity. <i>International Journal of Cancer</i> , 2004, 109, 200-206.	2.3	17
66	Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. <i>International Journal of Cancer</i> , 2003, 105, 384-389.	2.3	28
67	c-kit Receptor Expression in Ewing's Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate Conditions. <i>Journal of Clinical Oncology</i> , 2003, 21, 1952-1960.	0.8	71
68	Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. <i>Cancer Research</i> , 2003, 63, 2728-32.	0.4	53
69	HER/erbB Receptors as Therapeutic Targets of Immunotoxins in Human Rhabdomyosarcoma Cells. <i>Journal of Immunotherapy</i> , 2002, 25, 314-323.	1.2	29
70	Immunoprevention of colorectal cancer: a future possibility?. <i>Gastroenterology Clinics of North America</i> , 2002, 31, 1001-1014.	1.0	6
71	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. <i>Cancer Gene Therapy</i> , 2002, 9, 296-307.	2.2	101
72	Immunological prevention of spontaneous tumors: a new prospect?. <i>Immunology Letters</i> , 2002, 80, 75-79.	1.1	16

#	ARTICLE	IF	CITATIONS
73	Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells. <i>Gene</i> , 2001, 274, 139-149.	1.0	46
74	Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice. <i>Journal of Experimental Medicine</i> , 2001, 194, 1195-1206.	4.2	218
75	p185neu protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. <i>International Journal of Cancer</i> , 2000, 87, 186-194.	2.3	75
76	Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: Effects on tumorigenicity, metastatic potential and immune response. <i>International Journal of Cancer</i> , 2000, 87, 574-581.	2.3	56
77	Murine model for skeletal metastases of Ewing's sarcoma. <i>Journal of Orthopaedic Research</i> , 2000, 18, 959-966.	1.2	22
78	The prospects for cancer gene therapy. <i>International Journal of Immunopharmacology</i> , 2000, 22, 1025-1032.	1.1	7
79	Concomitant Amplification and Expression of PAX7-FKHR and MYCN in a Human Rhabdomyosarcoma Cell Line Carrying a Cryptic t(1;13)(p36;q14). <i>Cancer Genetics and Cytogenetics</i> , 2000, 121, 139-145.	1.0	20
80	DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice. <i>Journal of Immunology</i> , 2000, 165, 5133-5142.	0.4	326
81	The Metastatic Ability of Ewing's Sarcoma Cells Is Modulated by Stem Cell Factor and by Its Receptor c-kit. <i>American Journal of Pathology</i> , 2000, 157, 2123-2131.	1.9	73
82	The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. <i>Oncogene</i> , 1999, 18, 739-746.	2.6	35
83	Inhibition of lung colonisation of a mouse mammary carcinoma by therapeutic vaccination with interferon-alpha gene-transduced tumor cells. <i>Clinical and Experimental Metastasis</i> , 1998, 16, 123-128.	1.7	10
84	Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. , 1998, 77, 937-941.		58
85	Production of stem cell factor and expression of c-kit in human rhabdomyosarcoma cells: Lack of autocrine growth modulation. , 1998, 78, 441-445.		10
86	Interleukin 12-mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice. <i>Journal of Experimental Medicine</i> , 1998, 188, 589-596.	4.2	291
87	Expression of interleukin 15 (IL-15) in human rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma. , 1997, 71, 732-736.		17
88	Systemic effects of cytokines released by gene-transduced tumor cells: Marked hyperplasia induced in small bowel by $\hat{I}^3$ -interferon transfectants through host lymphocytes. <i>International Journal of Cancer</i> , 1995, 61, 425-430.	2.3	12
89	H-2Kb ANDH-2Db gene transfections in B16 melanoma differently affect non-immunological properties relevant to the metastatic process. Involvement of integrin molecules. <i>International Journal of Cancer</i> , 1994, 59, 269-274.	2.3	16
90	Inhibition of tumor growth and enhancement of metastasis after transfection of the $\hat{I}^3$ -interferon gene. <i>International Journal of Cancer</i> , 1993, 55, 320-329.	2.3	89

#	ARTICLE	IF	CITATIONS
91	Karyotypic characterization of a new human embryonal rhabdomyosarcoma cell line. <i>Cancer Genetics and Cytogenetics</i> , 1991, 54, 83-89.	1.0	10
92	Modulation by Ifn-Gamma of the Metastatic Ability of Murine, Human, and H-2-Transfected Tumor Cells. <i>Tumori</i> , 1989, 75, 383-388.	0.6	2
93	In vivo and in vitro production of haemopoietic colony-stimulating activity by murine cell lines of different origin: a frequent finding. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1989, 25, 1281-1286.	0.9	16
94	Interferon-Mediated Modulation of Metastasis and MHC Antigens. <i>Advances in Experimental Medicine and Biology</i> , 1988, 233, 129-139.	0.8	3
95	Heterogeneity and Clonal Interactions in the TS/A Murine Mammary Adenocarcinoma. <i>Advances in Experimental Medicine and Biology</i> , 1988, 233, 5-14.	0.8	4
96	Interferon-mediated enhancement of metastasis. Are MHC antigens involved?. <i>Clinical and Experimental Metastasis</i> , 1987, 5, 277-287.	1.7	29
97	Dexamethasone modulation of in vitro growth pattern and of lung colonization ability in clones of a metastatic BALB/c mammary carcinoma cell line. <i>Clinical and Experimental Metastasis</i> , 1986, 4, 13-23.	1.7	2
98	High-metastatic clones selected in vitro from a recent spontaneous BALB/c mammary adenocarcinoma cell line. <i>Clinical and Experimental Metastasis</i> , 1984, 2, 251-259.	1.7	20
99	TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. <i>Clinical and Experimental Metastasis</i> , 1983, 1, 373-380.	1.7	203
100	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. , 0, .		1